My watch list  


Systematic (IUPAC) name
CAS number 76963-41-2
ATC code A02BA04
PubChem 3033637
DrugBank APRD00706
Chemical data
Formula C12H21N5O2S2 
Mol. mass 331.46 g/mol
Pharmacokinetic data
Bioavailability >70%
Protein binding 35%
Metabolism Hepatic
Half life 1-2 hours
Excretion Renal
Therapeutic considerations
Licence data


Pregnancy cat.


Legal status

Prescription Only (S4)(AU) POM(UK)

Routes Oral

Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.

Clinical use

Main article: H2-receptor antagonist

Certain preparations of nizatadine are now available over the counter in various countries including the United States.

History and development

Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine.

Nizatidine proved to be the last new histamine H2-receptor antagonists introduced prior to the advent of proton pump inhibitors.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nizatidine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE